Table 3.
Clinicopathological feathers of AML patients with respect to TSS-A methylation.
| Characteristics | Hypomethylated TSS-A (n=117) |
Hypermethylated TSS-A (n=77) |
P-value |
|---|---|---|---|
| Median age, year | 60 (21-88) | 51 (18-76) | 0.0002 |
| Median hemoglobin, g/dL | 9 (6-14) | 9 (6-13) | 0.4800 |
| Median leukocytes, ×109/L | 15 (1-298) | 28 (1-297) | 0.3200 |
| Median monocytes, ×109/L | 22 (1-94) | 14 (0-91) | 0.0000 |
| Median platelet | 61 (9-351) | 36 (8-232) | 0.0001 |
| Median BM cellularity, % | 90 (10-100) | 90 (10-100) | 0.0017 |
| Median BM blast, % | 17 (0-96) | 48 (0-98) | 0.0200 |
| Median BM lymphocyte, % | 22 (1-94) | 14 (0-91) | 0.0200 |
| Median BM neutrophil, % | 6 (0-94) | 6 (0-46) | 0.7700 |
| Median TMB, Mut/Mb | 0.33 (0-0.90) | 0.27 (03-1.13) | 0.0200 |
| Gender (male/female) | 67/50 | 38/39 | 0.3500 |
| FAB | 0.0065 | ||
| M0 | 15 (7.73%) | 4 (2.06%) | 0.0897 |
| M1 | 21 (10.82%) | 21 (10.82%) | 0.1229 |
| M2 | 22 (11.34%) | 20 (10.31%) | 0.2354 |
| M3 | 6 (3.09%) | 13 (6.70%) | 0.0070 |
| M4 | 28 (14.43%) | 14 (7.22%) | 0.3414 |
| M5 | 18 (9.28%) | 4 (2.06%) | 0.0363 |
| M6 | 3 (1.55%) | 0 (0%) | 0.2782 |
| M7 | 3 (1.55%) | 0 (0%) | 0.2782 |
| Not Classified | 1 (0.52%) | 1 (0.52%) | 1.0000 |
| Cytogenetic abnormalities | 0.000 | ||
| Normal | 58 (32.95%) | 42 (23.86%) | 0.5594 |
| t (15;17) | 4 (2.27%) | 11 (6.25%) | 0.0061 |
| t (8;21) | 0 (0%) | 7 (3.98%) | 0.001 |
| inv (16) | 8 (4.55%) | 1 (0.57%) | 0.0684 |
| Trisomy 8 | 4 (2.27%) | 5 (2.84%) | 0.3319 |
| Complex | 21 (11.93%) | 3 (1.70%) | 0.0002 |
| del (7q)/7q- | 6 (3.09%) | 1 (0.52%) | 0.1549 |
| del (7q)/7q-|t (9;11) | 1 (0.52%) | 0 (0%) | 0.4118 |
| del (5q)/5q-|del (7q)/7q- | 2 (1.03%) | 0 (0%) | 0.2444 |
| del (5q)/5q- | 0 (0%) | 1 (0.57%) | 0.2204 |
| t (9;11) | 2 (1.14%) | 0 (0%) | 0.2444 |
| N/A | 12 (6.19%) | 6 (3.09%) | |
| Cytogenetic-risk categories | 0.0075 | ||
| Favorable | 16 (8.38%) | 20 (10.47%) | 0.0319 |
| Intermediate/Normal | 66 (34.55%) | 47 (24.61%) | 0.5402 |
| Poor | 33 (17.28%) | 9 (4.71%) | 0.0059 |
| N/A | 2 (1.03%) | 1 (0.52%) | |
| Gene mutations | |||
| DNMT3A mut (+/-) | 40/77 | 9/68 | 0.0008 |
| CEBPA mut (+/-) | 2/115 | 11/66 | 0.0017 |
| TP53 mut (+/-) | 16/101 | 0/77 | 0.0018 |
| RUNX1 mut (+/-) | 14/103 | 2/75 | 0.0400 |
| WT1 mut (+/-) | 3/114 | 8/69 | 0.0500 |
| NPM1 mut (+/-) | 26/91 | 27/50 | 0.0700 |
| IDH1 mut (+/-) | 10/107 | 9/68 | 0.6400 |
| NRAS mut (+/-) | 10/107 | 5/72 | 0.8000 |
| FLT3 mut (+/-) | 32/85 | 23/54 | 0.8300 |
| TET2 mut (+/-) | 9/108 | 7/70 | 0.9400 |
TSS-A, transcription start sites of GCNT2 isoform A; FAB, French–American–British subtypes; BM, bone marrow; TMB, tumor mutational burden; Mut/Mb, mutations per megabase.
Bold values highlight statistically significant differences, bold italic values indicate a trend toward significance.